12658 Federal Register / Vol. 62, No. 51 / Monday, March 17, 1997 / Notices

the capabilities of the expression

system. Synthesis of ‘native’ full-size

enzyme (92 kDa) will have highest

priority. Alternatively, a truncated TG1

with high activity and stability may be

tested (65 kDa). A standard

transglutaminase activity assay will be

used by the contractor to determine TG1

activity, and assess stability and optimal

storage conditions.

This CRADA aims include the rapid

development of a supply of active

human Transglutaminase I enzyme for

further characterization and research,

publication of research results and

possible exploitation of commercial

opportunities. The CRADA partner(s)

will enjoy rights of first negotiation for

licensing Government rights to any

inventions arising under the agreement.

The role of the NIAMS in this CRADA

will be as follows:

(1) Provide the Collaborator(s) with

samples of the clone gene DNA;

(2) Perform initial tests on

Collaborator produced test enzyme for

activity and function; and

(3) Provide expertise in optimizing

commercial development of this

compound to produce the most useful

product.

The role of the Collaborator will be as

follows:

(1) Produce high quality

Transglutaminase I in sufficient

quantities for research studies;

(2) Perform initial testing of

Transglutaminase I for purity; and

(3) Develop method(s) to produce

large quantities of Transglutaminase I

for commercial distribution.

Selection criteria for choosing the

CRADA partner(s) will include but not

be limited to:

(1) Ability to produce high quality

Transglutaminase I in large quantities

for research and evaluation;

(2) The level of financial support the

Collaborator will supply for the CRADA

related Government activities;

(3) A willingness to cooperate with

the NIAMS in the publication of

research results;

(4) An agreement to be bound by

DHHS rules involving human subjects,

patent rights, and ethical treatment of

animals; and

(5) Agreement with provisions for

equitable distribution of patent rights to

any inventions developed under the

CRADA(s).

Generally, the rights of ownership are

retained by the organization which is

the employer of the inventor with, (1) an

irrevocable, non-exclusive, royalty-free

license to the Government (when a

company employee is sole inventor) or

(2) an option to negotiate an exclusive

or non-exclusive license to the company

on terms that are appropriate (when the

Government employee is the sole

inventor).

Dated: March 4, 1997.

Sheila E. Merritt,

Executive Officer, NHLBI.

[FR Doc. 97–6634 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Heart,

Lung, and Blood Special Emphasis

Panel (SEP) meetings.

Name of SEP: Modeling DNA Diversity in

Cardiovascular Health/Disease.

Date: March 26–27, 1997.

Time: 7:30 p.m.

Place: Holiday Inn, Gaithersburg, #2

Montgomery Village Avenue, Gaithersburg,

Maryland 20879.

Contact Person: Anthony M. Coelho, Jr.,

Ph.D., Two Rockledge Center, Room 7194,

6701 Rockledge Drive, Bethesda, MD 20892–

7924, (301) 435–0299.

Purpose/Agenda: To review and evaluate

grant applications.

This notice is being published less than

fifteen days prior to this meeting due to the

urgent need to meet timing limitations

imposed by the review and funding cycle.

Name of SEP: Homocyst(E)inemia and

Atherosclerosis.

Date: April 10–11, 1997.

Time: 8:00 p.m.

Place: Ramada, 1775 Rockville Pike,

Rockville, Maryland 20852.

Contact Person: Eric H. Brown, Ph.D., Two

Rockledge Center, Room 7204, 6701

Rockledge Drive, Bethesda, MD 20892–7924,

(301) 435–0299.

Purpose/Agenda: To review and evaluate

grant applications.

The meetings will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health)

Dated: March 12, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6630 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of General Medical

Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

advisory committee meeting of the

National Institute of General Medical

Sciences:

Committee Name: Biomedical Research &

Research Training Subcommittee-A.

Date: March 12, 1997.

Time: 8:00 a.m. until 6:00 p.m.

Place: Bethesda Holiday Inn, 8120

Wisconsin Avenue, Pennsylvania Room,

Bethesda, Maryland 20814.

Contact Person: Carole H. Latker, Ph.D.,

Office of Scientific Review, Scientific Review

Administrator, NIGMS, 45 Center Drive,

Room 1AS–19G, Bethesda, MD 20892–6200,

301–594–2848.

Purpose: To review institutional research

training grant applications.

This meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

Applications and the discussions of these

could reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

This notice is being published less than 15

days prior to the above meeting due to the

urgent need to meet timing limitations

imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.821, Biophysics and

Physiological Sciences: 93.859,

Pharmacological Sciences; 93.862, Genetics

Research; 93.863, Cellular and Molecular

Basis of Disease Research; 93.880, Minority

Access Research Careers [MARC]; and

93.375, Minority Biomedical Research

Support [MBRS])

Dated: March 12, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6626 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Arthritis and

Musculoskeletal and Skin Diseases;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Arthritis and

Musculoskeletal and Skin Diseases

Special Emphasis Panel (SEP) meeting:

Name of SEP: Gene Therapy for

Epidermolysis Bullosa.

Date: April 4, 1997.

Time: 8:30 a.m.–adjournment.

Place: Holiday Inn Bethesda, 8120

Wisconsin Avenue, Bethesda, Maryland

20814.